Medicines labeled for the same conditions
Alternatives to empagliflozin and linagliptin
31 other medicines are given the same way (oral) and in the same FDA class as empagliflozin and linagliptin or labeled mainly for the same use (type 2 diabetes); 14 are in its class, sodium-glucose cotransporter 2 inhibitors: dapagliflozin, dapagliflozin and metformin, metformin and sitagliptin, sitagliptin and 10 more; the others include 5 sulfonylureas, 3 peroxisome proliferator receptor gamma agonists and 2 biguanides (FDA labels read October 8, 2026). In the same class, the lowest pharmacy cost is $0.184 per dapagliflozin 10 mg tablet (what pharmacies paid in the NADAC survey; strengths differ).
Which medicines are labeled for the same conditions as empagliflozin and linagliptin?
The first 24 of the 31, the same class first. Type 2 diabetes lists all 52 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (oral) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Empagliflozin and linagliptinsodium-glucose cotransporter 2 inhibitor | this medicine | none listed | $11.24 per tablet 10 mg-5 mg tablet | No | No current entry |
| Dapagliflozinsodium-glucose cotransporter 2 inhibitor · same class | Type 2 diabetes | 22 labelers | $0.184 per tablet 10 mg tablet | No | No current entry |
| Dapagliflozin and metforminsodium-glucose cotransporter 2 inhibitor · same class | Type 2 diabetes | 8 labelers | $0.720 per tablet 10-1,000 mg tablet | Yes | No current entry |
| Metformin and sitagliptindipeptidyl peptidase 4 inhibitor · same class | Type 2 diabetes | 4 labelers | $1.76 per tablet 50 mg-1,000 mg tablet | Yes | No current entry |
| Sitagliptindipeptidyl peptidase 4 inhibitor · same class | Type 2 diabetes | 4 labelers | $3.77 per tablet 100 mg tablet | No | No current entry |
| Alogliptindipeptidyl peptidase 4 inhibitor · same class | Type 2 diabetes | none listed | $4.96 per tablet 12.5 mg tablet | No | No current entry |
| Alogliptin and pioglitazoneperoxisome proliferator receptor gamma agonist · same class | Type 2 diabetes | none listed | $4.73 per tablet 25-15 mg tablet | Yes | No current entry |
| Canagliflozin and metforminsodium-glucose cotransporter 2 inhibitor · same class | Type 2 diabetes | none listed | $9.58 per tablet 150-1,000 mg tablet | Yes | No current entry |
| Canagliflozinsodium-glucose cotransporter 2 inhibitor · same class | Type 2 diabetes | none listed | $19.13 per tablet 100 mg tablet | No | No current entry |
| Metformin and saxagliptindipeptidyl peptidase 4 inhibitor · same class | Type 2 diabetes | 2 labelers | $9.65 per tablet 5-1,000 mg tablet | Yes | No current entry |
| Saxagliptindipeptidyl peptidase 4 inhibitor · same class | Type 2 diabetes | 3 labelers | $1.04 per tablet 5 mg tablet | No | No current entry |
| Alogliptin and metformindipeptidyl peptidase 4 inhibitor · same class | Type 2 diabetes | none listed | $2.46 per unit 12.5-1000 | Yes | No current entry |
| Bexagliflozinsodium-glucose cotransporter 2 inhibitor · same class | Type 2 diabetes | none listed | n/a | No | No current entry |
| Ertugliflozin and sitagliptindipeptidyl peptidase 4 inhibitor · same class | Type 2 diabetes | none listed | $17.59 per tablet 15-100 mg tablet | No | No current entry |
| Dapagliflozin and saxagliptinsodium-glucose cotransporter 2 inhibitor · same class | Type 2 diabetes | 1 labeler | n/a | No | No current entry |
| Metforminbiguanide | Type 2 diabetes | 83 labelers | $0.0145 per tablet 500 mg tablet | Yes | No current entry |
| Glipizidesulfonylurea | Type 2 diabetes | 31 labelers | $0.0339 per tablet 5 mg tablet | No | No current entry |
| Glimepiridesulfonylurea | Type 2 diabetes | 29 labelers | $0.0507 per tablet 4 mg tablet | No | No current entry |
| Pioglitazoneperoxisome proliferator receptor gamma agonist | Type 2 diabetes | 22 labelers | $0.0675 per tablet 15 mg tablet | Yes | No current entry |
| Glyburidesulfonylurea | Type 2 diabetes | 16 labelers | $0.0643 per tablet 5 mg tablet | No | A presentation being discontinued |
| Glyburide and metforminsulfonylurea | Type 2 diabetes | 11 labelers | $0.171 per unit 2.5-500 mg | Yes | No current entry |
| Glipizide and metforminsulfonylurea | Type 2 diabetes | 9 labelers | $0.242 per unit 2.5-250 mg | No | No current entry |
| Repaglinideglinide | Type 2 diabetes | 7 labelers | $0.0987 per tablet 1 mg tablet | No | No current entry |
| Nateglinideglinide | Type 2 diabetes | 9 labelers | $0.179 per tablet 60 mg tablet | No | No current entry |
| Acarbosealpha-glucosidase inhibitor | Type 2 diabetes | 6 labelers | $0.274 per tablet 100 mg tablet | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Empagliflozin and linagliptin: the full record
- label, generics, price, shortages, recalls